International Journal of Health Sciences and Engineering (IJHSE)
Website: https://ijhse.com
ISSN: 3049-3811
Vol. 2, Issue 1, Jan-June, 2026
Page No.: 01-16

Review

Immunological Memory in Viral Infections: Lessons from COVID-19

Vivaswaan Pandey
Master's Student, University of Lucknow, Lucknow, India

Corresponding Author:
Vivaswaan Pandey

Email:
vivaswaanpandey@gmail.com

Conflict of interest: *NIL*

DOI: *10.62896/ijhse.v2.i1.01*

Article History
Received: 03/11/2025
Accepted: 13/12/2025
Published: 08/01/2026

Abstract:
Immunological memory is basically the immune system's way of not starting from scratch every time it sees a virus. Once the body has gone through that first encounter, the next one is usually quicker and more effective-though how well this works can depend a lot on the virus itself. B cells and T cells are the central players here, but over the past few years scientists have noticed that even some innate immune cells can be "trained" to respond a little better the second time. The strength and the durability of this memory, however, are uneven. Some viruses, like measles, give protection that pretty much lasts a lifetime. Others, such as the seasonal coronaviruses, don't leave much of a lasting impression at all, which is why people can keep catching them. COVID-19 came along and forced researchers to study these differences in real time. Both infection and vaccination against SARS-CoV-2 create a layered form of immune memory-antibodies at first, but also memory B cells and T cells that stick around. The antibody levels fade within a few months, but the cellular memory seems to last longer and has been especially important in preventing serious disease. Vaccination, especially with the mRNA platforms, has turned out to be very effective in building this long-term memory. And when people have both infection and vaccination- so-called hybrid immunity- the protection is broader and more durable than either alone. That said, the story isn't finished. People respond differently depending on age and health, the virus itself keeps mutating, and the current vaccines don't really boost mucosal immunity in the respiratory tract. Understanding all of this in the context of COVID-19 doesn't just help with today's vaccine strategies- it also gives clues for how we might handle whatever virus shows up next.

Keywords: Immunological Memory, Immune System, Cellular Memory, Vaccination, mRNA vaccin

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

1. Introduction

Immunological memory might sound like a technical term, but at its heart it's just the immune system's ability to remember. After the first brush with a virus, the body rarely forgets. The second time around, instead of fumbling, it moves quickly- producing antibodies faster, mobilizing T cells more efficiently, and usually controlling the infection before it gets out of hand. This is why so many viral infections, and the vaccines designed to mimic them, can provide long stretches of protection. Measles, polio, and smallpox are all reminders of how powerful this memory can be when it's solid and long-lasting.

The COVID-19 pandemic threw this old concept into the spotlight in a way no one expected. Suddenly, the question wasn't just theoretical: does infection with SARS-CoV-2 - or a vaccine against it - leave behind immunity that lasts? Early worries weren't unfounded. After all, immunity to seasonal coronaviruses is notoriously short-lived, which explains why people catch colds caused by them

International Journal of Health Sciences and Engineering (IJHSE)
Website: https://ijhse.com
ISSN: 3049-3811
Vol. 2, Issue 1, Jan-June, 2026
Page No.: 01-16

again and again. Would COVID-19 follow the same pattern, or would it behave differently?

Of course, immune memory is not a single, simple process. B cells and plasma cells generate antibodies, some of which linger, while memory B cells sit quietly until they're needed again. Helper and killer T cells add another layer of defence, helping coordinate responses or wiping out infected cells directly. More recently, scientists have even started talking about "trained immunity," where innate cells - long thought to be nonspecific - get reprogrammed in ways that make them respond more strongly to later encounters. Each of these layers contributes in its own way, depending on the virus and the context.

With COVID-19, the story turned out to be complicated but somewhat encouraging. Antibodies peak early and then drop within months, but memory B and T cells stick around much longer, often making the difference between a mild illness and severe disease. Vaccines, particularly the new mRNA ones, demonstrated just how effectively this memory can be built from scratch. And when natural infection and vaccination combine, the result often called hybrid immunity seems to produce the strongest and broadest protection of all. But variants of the virus quickly reminded everyone that immune memory, though powerful, is not unshakable.

This review sets out to bring together what we currently know about immunological memory in viral infections, using COVID-19 as a central case study. First, the mechanisms of immune memory will be outlined. Then, examples from other well-studied viruses will provide context, before turning back to SARS-CoV-2 to look at how infection, vaccination, and hybrid immunity compare. Finally, the review will discuss ongoing challenges and consider what all of this means for vaccine development and pandemic preparedness in the future.(Sette and Crotty, 2021)

2. Background: Mechanisms of Immunological Memory

Immunological memory develops once the immune system has already "met" a pathogen. After that first encounter whether through actual infection or vaccination the body doesn't go in blind again. The next time around, the response is noticeably quicker and usually more effective. This is really the foundation of how protective immunity works, and why vaccines have been so successful. For years, scientists thought of this as the exclusive domain of adaptive immunity, but more recently it has become clear that the innate side also has a way of leaving behind a kind of imprint.



Mechanism of Immunological Memory

2.1 B Cell Memory and Antibody-Mediated Immunity

When a virus first infects someone, naïve B cells kick into gear. Some of them turn into short-lived plasma blasts that produce a flood of antibodies during the peak of illness. Others take a slower path and become plasma cells that set up shop in the bone marrow, quietly putting out antibodies for the long haul.

At the same time, a reserve of memory B cells is created. They don't do much right away-they just linger, like soldiers waiting on standby. If the same

virus comes back, though, these cells react quickly. In fact, through processes like affinity maturation, they can produce antibodies that actually fit the virus better the second time around. So even when antibody levels in the bloodstream fade after a few months, the presence of memory B cells means the immune system is still primed to respond.

2.2 T Cell Memory

T cells are just as important, especially for viruses that hide inside our own cells. After an infection, most of the activated T cells die off, but a small population remains as memory cells. These don't all act the same.

Some, known as central memory T cells, tend to stay in lymphoid tissues, ready to expand if the antigen reappears. Effector memory T cells roam more freely through the body's tissues, ready to act quickly if they spot the enemy. And then there are the tissue-resident T cells that never leave their post. They stay put in places like the lungs or the gut, where reinfections are most likely to happen. Together, they form a sort of layered defence - some responding immediately, others providing a longer-term backup.

2.3 Innate Immune Memory (Trained Immunity)

For a long time, it was assumed that innate immunity was fast but forgetful. You got the immediate defence, but nothing lasting. That view has shifted. Studies now show that innate cells - macrophages, dendritic cells, NK cells - can be "trained" to respond more strongly the next time they're triggered. It isn't antigen-specific like adaptive memory. Instead, it happens through epigenetic and metabolic changes that alter how these cells function.

A classic example is the BCG vaccine. Although designed for tuberculosis, it has been observed to boost resistance against other, unrelated pathogens. This kind of trained immunity may not provide sterilizing protection against viruses, but it can give the immune system a head starts and influence how adaptive responses develop later.

2.4 Integration of Memory Responses

In practice, these different memory systems don't operate in isolation. Antibodies may block infection at the door, but if some virus slips through, T cells take on the heavier job of controlling it. Trained innate immunity can add another layer, acting like an early-warning signal. The mix of these contributions is not the same for every virus. That's why some infections, like measles, leave behind immunity that can last for decades, while others, like seasonal coronaviruses, provide only temporary protection.(Dan et al., 2021)

Table 1 – Components related to Immunological memory and their Function

Component	Function	Duration	Special Features
Memory B cells	Generate high-affinity antibodies upon re-exposure	Years to decades	Affinity maturation improves quality over time
Long-lived plasma cells	Maintain baseline circulating antibodies	Years	Reside in bone marrow; independent of antigen presence
Memory $CD4^+$ T cells	Support B cell and $CD8^+$ T cell responses	Years	Central role in coordinating immune responses
Memory $CD8^+$ T cells	Kill infected cells and limit viral spread	Years (half-life ~125–190 days initially)	Subsets: T_CM, T_EM, T_RM
Tissue-resident memory T cells (T_RM)	Provide local frontline defence	Variable	Persist at mucosal/epithelial surfaces
Trained innate immunity	Enhance nonspecific early responses	Months to years (still under study)	Epigenetic and metabolic reprogramming

(Minervina et al., 2021; Tarke et al., 2022)

3. Immunological Memory in Viral Infections: General Examples

Not every virus leaves the same kind of memory behind. Some stick so firmly in the immune system's "notebook" that one encounter is enough for life. Others barely

leave a trace, which is why people can catch them again and again. The reasons vary - sometimes it's about how fast the virus mutates, sometimes about where it infects, and sometimes it's just the way our immune system handles it. A few cases make this clear.

Aspect	**Durable/Strong Memory (e.g., Measles ,HBV)**	**Weak/Temporary Memory (e.g., Influenza, Seasonal Coronaviruses).**
Initial Response	High antibody peak from long-lived plasma cells ,strong primary activation of B and T cells.	High antibody peak, but from short lived plasma cells; initial activation is robust but not sustained.
Antibody Persistence	Sustained levels for decades; Affinity- matured IgG from memory B cells in bone marrow.	Rapid decline within months; waning due to weaker memory B cells and antigenic drift.
T Cell Memory	Robust and diverse; Central effector ,and tissue-resident T cells provide lifelong surveillance	Limit duration: Shorter lived effector memory; partial protection against variants.
Integration with Innate Immunity	Strong epigenetic imprinting enhances adaptive responses; Trained immunity reinforces long term protection	Weaker trained immunity; less influence on adaptive recall, Leading to breakthrough infection.
Outcome	Long-term/lifelong protection; rare reinfection; often sterilizing immunity(e.g. measles eradication potential).	Frequent reinfection; temporary protection requires boosters; common breakthrough(e.g. annual flu shots).

Table 2 -Comparison between Strong and Weak Memory
(Adusumilli NC, et al 2022)

Measles is often used as the textbook example of durable memory. People who recover from it almost never get it a second time. That's because both neutralizing antibodies and memory T cells stay around for decades, often for life. The measles vaccine, even though it's just an attenuated version of the virus, does nearly the same job. Many adults who were vaccinated as children are still protected without needing boosters. In short, measles shows how strong and lasting immune memory can be when everything works in our favour.

Influenza is frustratingly different. Yes, an infection or a flu shot produces antibodies and some T cell memory, but the virus keeps changing its appearance. Its surface proteins - hemagglutinin and neuraminidase - mutate often enough that last year's antibodies may not work on this year's strain. This constant antigenic drift is why immunity to flu doesn't last very long and why new vaccines are needed every year. It's not that the immune system forgets; it's that the virus changes its disguise.

Hepatitis B offers another lesson. After recovery or vaccination, antibody levels may slowly decline, sometimes to the point where they're barely detectable. Yet, memory B and T cells remain in the background. If the virus shows up again, these memory cells react quickly, often before illness can develop. That's why, for most healthy people, booster doses of the HBV vaccine aren't required, even if blood tests show low antibodies. The memory itself is what counts.

HIV poses a very different challenge. The immune system does mount a response, but HIV mutates rapidly and finds ways to escape. To make matters worse, it directly targets $CD4^+$ T cells, which are themselves essential for building long-term memory. So, unlike measles or hepatitis B, infection with HIV does not result in protective immunity. Once a person is infected, the virus establishes itself permanently. This is a major reason why, despite enormous global efforts, a successful HIV vaccine has remained out of reach.

The seasonal coronaviruses that cause colds - like OC43 and 229E - are another reminder of weak immune memory. People often catch them again within a year or two. The main reason is that antibody levels drop quickly, and the memory response they leave behind isn't particularly strong

or long-lived. This was worrying at the start of the COVID-19 pandemic, because many feared SARS-CoV-2 would follow the same pattern. But interestingly, evidence suggests memory to SARS-CoV-2 has been more robust than its milder relatives, even if not as lasting as measles.(Turner et al., 2021)

Virus	Immune Memory Duration	Key Features
Measles	Lifelong	Robust neutralizing antibodies, T cell memory
Influenza	Months to years	Antigenic drift undermines memory; annual vaccination needed
Hepatitis B	Long-lasting despite waning antibodies	Memory B/T cells provide recall responses
HIV	No sterilizing immunity	Virus mutates rapidly, targets $CD4^+$ T cells
Seasonal coronaviruses	1–2 years	Reinfections common; limited durability of memory
SARS-CoV-2	≥18–24 months (B/T cells)	Antibodies wane, but cellular memory persists; variant impact significant

Table 3 – Some general examples of diseases caused by viruses
(Stankov MV, et al, 2023)

4. Pathogenicity of Covid 19

COVID-19 doesn't follow one simple path. The same virus can give one person mild cold-like symptoms and push another into organ failure. It's not only what the virus does-it's how the body reacts. The fight between SARS-CoV-2 and the immune system decides the outcome, and that fight isn't always fair. Sometimes the immune system is late. Sometimes it overreacts.

1. How the Virus Gets in and Spreads

The virus uses its spike protein like a key, fitting into the ACE2 receptor on our cells. Those receptors are everywhere-lining the lungs, in the gut, even in blood vessels. Once attached, a few enzymes (TMPRSS2 and furin, for instance) help the virus unlock the cell and slip inside. From there, it turns part of the cell into a workshop, using little double-membrane bubbles to copy its RNA out of sight.

When enough copies are made, they move out and infect nearby cells. In the first week, the virus mostly stays in the upper airways. That's when people are most contagious. If it makes its way deeper into the lungs, the story starts to change-less about viral growth and more about inflammation and damage caused by the body's own defences.

2. The Early Alarm That Doesn't Always Ring

Normally, our cells notice viral RNA quickly. They have built-in sensors-things like RIG-I and TLR7-that send a signal to produce interferons. These interferons act like an alarm, warning neighbouring cells and slowing the virus down. But SARS-CoV-2 has learned to muffle that alarm. Some of its proteins block the signal, while others stop cells from showing the usual "danger" signs.

This delay is dangerous. The virus gets a head start, multiplying quietly. When the immune system finally wakes up, it reacts hard-and sometimes too late.

3. When the Immune System Overreacts

In severe cases, the response turns chaotic. The body releases floods of cytokines-IL-6, TNF, IL-1β-and they pull in immune cells like neutrophils and monocytes. These cells come rushing in, releasing enzymes and chemicals meant to kill the virus but that end up damaging tissue too.

You can imagine the lungs at this point: inflamed, leaky, filling with fluid. Oxygen can't move properly into the blood. Doctors call it ARDS, and it's one of the biggest killers in severe COVID-19. The same inflammation also affects blood vessels, making them prone to clotting. Micro clots form in the lungs, heart, and brain. Meanwhile, T cells-the virus fighters-start disappearing or become "exhausted." They're present, but too tired to work.

4. It's Not Just a lung disease

Although it starts in the lungs, SARS-CoV-2 doesn't always stay there. ACE2 receptors are found in many other organs, and that's why symptoms can appear almost anywhere.

- Heart and blood vessels: The virus can infect the cells that line them, causing swelling and clots. That's why heart attacks and strokes appear even in younger patients.

- Kidneys and liver: These organs get hit both directly and by the storm of inflammation. It's common to see kidney injury and raised liver enzymes.
- Brain and nerves: Loss of smell, brain fog, and headaches may come from the virus or from inflammation in nearby blood vessels.
- Gut: The virus can infect intestinal cells too, leading to diarrhoea and changes in gut bacteria, which might even affect immunity later.

So, COVID-19 isn't just a "lung infection." It's more like a chain reaction that spreads inflammation through multiple systems.

5. How the Virus Hides

SARS-CoV-2 doesn't simply run it hides. The spike protein is wrapped in sugar molecules that block antibodies from grabbing on easily. Inside cells, other viral proteins block the interferon system or prevent infected cells from showing bits of the virus on their surface. That makes it harder for killer T cells to find and destroy them.

Over time, new variants like Delta and Omicron changed their spike protein shape, dodging existing antibodies even more effectively. That's part of why reinfections happen and why immune memory sometimes feels weaker than expected.

6. Why Some People Get Sicker

Not everyone's immune system fights on equal footing. Age matters a lot-older people tend to have slower and less coordinated responses. Their interferon system doesn't work as sharply, and chronic inflammation makes everything worse. The same goes for conditions like diabetes, obesity, or heart disease. These keep the body in a constant "alert" state even before infection, so when the virus hits, the reaction can be exaggerated.

There are also rare genetic differences. Some people have small defects in the genes that control antiviral defence. Others have autoantibodies that block interferons completely, as if their own defence system is sabotaging them. Even gender plays a role: males often mount stronger inflammatory responses but weaker adaptive immunity, which might help explain why severe cases are more common in men.

7. How the Battle Shapes Memory

What happens during infection also decides how the immune system remembers it later. A strong, well-timed response usually leaves behind long-lasting B and T cell memory. People who had severe infections often develop stronger, more durable protection. But that's not the whole story. Too much inflammation can destroy the very structures that make memory-germinal centres in lymph nodes-and even kill lymphocytes outright.

Milder infections, which are more common, tend to create weaker memory. It's a trade-off: less inflammation means less damage, but also a smaller immune imprint. The goal is balance-clear the virus effectively without wrecking the system that needs to remember it.

8. In Short

COVID-19's pathogenicity is basically the story of imbalance. The virus spreads fast, the immune system catches up late, and the inflammation that's supposed to protect sometimes turns destructive. The outcome depends on timing, viral load, genetics, and health. Understanding that tug-of-war helps explain why some people build strong immunity while others struggle, and why the same virus behaves so differently from person to person.(Gaebler et al., 2021)

5. Diseases and Complications Related to COVID-19 Infection

When COVID-19 first appeared, most people thought it was just another chest infection. But it turned out to be far more complicated. The virus doesn't stay politely in the lungs; it can reach almost any organ it finds access to. What actually happens depends on how much virus enters, how strong or late the immune reaction is, and whether a person already has other health issues. Sometimes the immune system keeps balance; other times it goes off course and adds to the injury instead of stopping it.

The lungs face the first and hardest hit. That's why fever, coughing, and breathlessness come early. The virus infects the airway lining and the tiny air sacs where oxygen moves into the blood.

Pneumonia: Inside those air sacs, inflammation spreads quickly. Type II pneumocytes-the cells that make surfactant to keep the lungs from collapsing-get damaged. The air spaces fill with fluid and dead cells, making oxygen transfer difficult.

Acute Respiratory Distress Syndrome (ARDS): If the inflammation keeps building, the lungs stiffen, the air sacs close, and breathing turns into a struggle. COVID-related ARDS looks similar to what severe

flu does, but here you also see many small clots blocking the vessels.

Pulmonary Fibrosis: Even after the infection clears, the repair process can overshoot. Fibroblast cells lay down scar tissue, leaving parts of the lung thick and less elastic. That's why some people keep feeling short of breath months later.

On scans you often see "ground-glass" cloudy areas or patchy stripes-the classic fingerprint of COVID-19 lung damage.

COVID-19 doesn't ignore the heart or blood vessels. The virus can infect the inner vessel lining, and once that happens, inflammation and clotting follow fast.

Myocardial Injury and Myocarditis: High troponin readings tell doctors the heart muscle is stressed. Sometimes that's direct viral entry; sometimes the immune response itself causes it.

Arrhythmias and Heart Failure: Low oxygen, swelling, and electrolyte swings can throw off the heart's rhythm. People with earlier heart problems are hit hardest, but even others may develop new rhythm issues or temporary failure.

Thromboembolic Events: The infection makes blood unusually sticky. Clots can form deep in the legs, travel to the lungs, or block brain arteries, leading to stroke.

Multisystem Inflammatory Syndrome (MIS-A): A few adults, weeks after recovery, face a sudden flare of inflammation-fever, rash, heart inflammation-much like Kawasaki disease.

Months later, the risk of heart attack or chronic heart weakness remains higher than before infection, which shows how long its footprint lasts.

The virus also finds its way into the nervous system, sometimes through blood, sometimes through the nerves in the nose.

Acute Symptoms: Loss of smell or taste, headaches, dizziness, confusion-all common. Some people progress to seizures or even encephalitis.

Stroke: Because the vessels are inflamed and clots form easily, both ischemic and bleeding strokes can occur.

Peripheral Neuropathies: A few weeks after infection, the immune system can misfire and attack nerves, causing Guillain–Barré-type paralysis.

Neuropsychiatric Effects: After recovery, many report brain fog, anxiety, or low mood. Ongoing neuro-inflammation and poor blood flow seem to play a role.

These effects remind us that COVID-19 doesn't stop at breathing-it can quietly interfere with how the brain and nerves work.

The kidneys and liver, full of ACE2 receptors, also get drawn in.

Acute Kidney Injury (AKI): Hospitals have seen many COVID patients suddenly lose kidney function. Direct viral infection, inflammation, and clots combine to damage the filtering units. Some never fully regain baseline function.

Liver Damage: Raised enzymes like ALT and AST show up in tests. Sometimes it's direct viral stress; other times it's side effects from heavy medication or the general storm of inflammation.

Longer-Term Changes: A few people later develop mild fatty liver or problems with bile flow, hinting that the virus may set off metabolic disturbances that linger.

The gut is another easy entry point because it's packed with ACE2 receptors. That's why diarrhoea, nausea, or stomach cramps often appear. Viral RNA has been found in stool long after nasal swabs turn negative, suggesting the virus may hang around there.

The gut microbiome also shifts-a loss of healthy diversity that can keep the immune system slightly unsettled.

Endocrine problems aren't rare either. The virus can harm pancreatic β-cells, causing short-term spikes in blood sugar or even new diabetes. Thyroid and adrenal glands can also become inflamed, probably from the body's confused immune attack after infection.

Skin and muscles tell their own story.

Vasculitic Lesions: Many have seen "COVID toes," purplish spots caused by small-vessel inflammation. Similar mottled rashes or purpura come from the same process.

Rashes and Drug Reactions: Itchy welts or red blotches appear during treatment, linked either to immune complexes or medicine sensitivity.

Muscle and Joint Pain: General tiredness, aching, and weakness are among the most reported after-effects. Inflammation and low cellular energy output (mitochondrial stress) explain much of it.

Long after the infection clears, a surprising number of people still don't feel right. This is now called Long COVID, or PASC.Fatigue, shortness of breath, fuzzy thinking, joint stiffness, and poor sleep top the list. Research finds traces of inflammation still

active and, in some, auto-antibodies that attack self-tissues.

Bits of viral protein may linger in organs, keeping the immune system half-alert. That low-grade activation could delay full recovery and affect how durable immune memory becomes.Children usually pass through infection mildly, yet a few develop MIS-C several weeks later. It brings high fever, rashes, stomach upset, and heart inflammation. The illness isn't caused by live virus but by the immune system going into overdrive.

It resembles Kawasaki disease and toxic shock. Fortunately, with early steroids or immune-calming drugs, most children recover fully. Still, MIS-C shows how even mild cases can echo later as strong immune flare-ups.COVID-19 leaves its fingerprints everywhere-lungs, heart, brain, kidneys, gut, and skin. The virus causes direct injury, but the body's over-reaction often deepens the harm. Lung scarring, clot formation, nerve problems, lingering fatigue-all stem from that mix.Even months later, traces of inflammation or viral debris may keep the immune system uneasy, shaping how lasting immunity forms. Understanding these widespread effects isn't just about treating symptoms; it's about learning how the body remembers this infection and prepares for the next one.(Naranbhai et al., 2022)

6. Immunological Memory in COVID-19 (SARS-CoV-2)

Our understanding of our body's defensive mechanism has evolved as a result of the investigation of immunological memory in COVID-19. When SARS-CoV-2 first emerged, it presented unprecedented challenges to the immune system. From the initial perplexed reaction to a consistent, enduring memory, scientists could virtually observe the learning process in action. It became evident over time that memory B and T cells silently remain behind, recalling the virus long after recovery, whereas antibodies rise and fade swiftly. Because of these memory cells, many individuals who have already contracted the virus hardly ever get really sick again. Predicting the likelihood of reinfection, enhancing vaccinations, and controlling future outbreaks all depend on an understanding of how this memory develops and persists.

The immune system responds immediately once the virus enters the body. The natural response, the initial stage, is quick but imprecise. The natural killer (NK) cells, interferons, and macrophages all work to slow the virus down. The adaptive immune system takes over a few days later. This phase, which uses B and T cells to develop a long-term strategy, is longer to begin but much more focused.(Krammer, 2021)

The majority of SARS-CoV-2 infections result in a robust adaptive response. Usually appearing ten days after the onset of symptoms, neutralizing antibodies that prevent the virus from entering cells peak three to five weeks later. Antibody levels then begin to decline, which may seem concerning until you learn that the body maintains a "memory copy" of how to combat the virus. B and T cells contain such memory. Although they don't always totally prevent reinfection, they function quickly enough to keep the sickness considerably less severe. Because of this innate memory, subsequent infections hardly ever worsen.

Memory B cells are the archivists of the immune system's defences; they remember what worked the last time. They primarily identify the spike and nucleocapsid proteins of COVID-19. These B cells are still present and prepared to respond at any time after the initial spike in antibodies subsides. It's interesting to note that these cells continue to improve. They eventually increase their ability to attach to the virus by using somatic hypermutation to refine their antibody patterns inside germinal centres. It appears as though the immune system continues to function even after the virus has cleared up**.**

Even minor illnesses leave a solid foundation of B-cell memory, but people who have experienced severe sickness tend to have higher antibody levels. Some of these memory B cells are even able to identify related coronaviruses or more recent variations. Memory B cells wait to increase production, when necessary, while long-lived plasma cells silently produce trace amounts of antibodies deep within the bone marrow.

Free-floating virus particles are neutralized by antibodies, but T cells take over once the virus has hidden inside a cell. While $CD4^+$ helper T cells direct the rest of the immune system, $CD8^+$ T cells are the direct assailants, eliminating contaminated cells.

A pool of memory T cells is developed by almost all COVID-19 survivors. These target not just the spike protein but also the membrane and nucleocapsid

proteins, among other viral features. This gives T-cell memory a remarkable range and makes it more difficult for variations to escape.

There are various kinds:

When reactivated, central memory T cells (T_CM) remain in lymph nodes and proliferate rapidly. T cells with effector memory (T_EM) move across tissues and are prepared for quick defence. resident memory T cells (T_RM) are found in the throat, lungs, and nose, which is precisely where the virus tries to enter the body.

T-cell responses, which produce chemicals like granzyme B and interferon-gamma to limit viral replication, have been observed to persist for more than two years. The majority of T-cell targets remain constant over variations, which is another encouraging discovery. This means that even when antibodies get weaker, they can still provide protection against serious illness.

The earliest fight against SARS-CoV-2 typically begins in the nose and throat, even if systemic immunity covers the entire body. Mucosal immunity can help with it. It depends on tissue-resident T lymphocytes that serve as sentries at the entry sites and secretory IgA antibodies.

These defences are effectively stimulated by natural infection. Before the virus spreads farther into the lungs, IgA antibodies can kill it after they have formed in the airways. This prompt action reduces transmission and restricts infection. IgA levels fall within a few months; therefore, mucosal protection is not as durable as systemic immunity.

Most vaccinations don't strongly elicit mucosal responses because they are administered by injection. Because of this, despite the fact that vaccinations protect against major sickness, vaccinated individuals may still contract minor or symptomless infections. Researchers are currently investigating oral and nasal vaccines that may strengthen local immunity, which prevents illness before it starts. The rate at which certain immunological memory components deteriorate varies. B and T cells survive for a lot longer than neutralizing antibodies, which disappear after a few months. According to studies, memory CD8 T cells level out into a stable phase after a half-life of roughly six months.

This is supported by evidence from past coronavirus outbreaks. Nearly twenty years after the 2003 SARS outbreak, memory T cells were still detected in people who recovered. Similar patterns are showing up for SARS-CoV-2, indicating that the cellular component of protection may persist for a long time. This memory guarantees that the body responds promptly even in the event of reinfection. The majority of reinfections are much less severe because, although the virus may enter, it seldom spreads very far. According to global data, natural infection offers robust protection for up to eight months, with an 80–95% chance of avoiding reinfection with the initial strain. The changes in variants like Delta and Omicron produce a minor decrease in protection, but the body still tends to avoid serious illness.

Each person has a different immunological memory strength. While moderate or silent instances have smaller responses, severe infections frequently produce larger, more persistent ones. Even a small immunological memory, however, frequently accomplishes its goal of making the subsequent infection controllable and non-threatening.

Immune memory has a highly human side that goes beyond numbers. It's how our bodies remember things, an internal journal of all the difficulties we've faced and conquered. After recovering from COVID-19, millions of people now have immunological "footprints" that subtly shield them.

Something about that is noteworthy. The immune system learns, not just reacts. It retains a record of that interaction, a form of biological knowledge, so that it can be more efficient and intelligent the next time. It serves as a reminder that resilience is ingrained in our bodies and is not only psychological.

Strategies for vaccines have changed as a result of the insights learned from researching COVID-19 immunity. Researchers have been able to improve booster timing and select more effective targets for next-generation vaccinations by understanding how memory arises.

"Hybrid immunity"-from both illness and vaccination-has become widespread in many nations. Individuals that possess this combination typically exhibit more robust and adaptable reactions that can manage a greater variety of variations. It's encouraging that the immune system is able to adjust to the virus's constant changes.

A multilayer immunological memory is left behind by SARS-CoV-2 infection, consisting of memory B and T cells, antibodies, and mucosal defences that work together to offer long-lasting protection. Even though antibodies can wane, B and T cells' deeper memory endures, guaranteeing that subsequent interactions will be less severe and brief.

7. Vaccination and Memory Responses in COVID-19

The arrival of COVID-19 vaccines changed the course of the pandemic, but it also gave us an unusual opportunity. For once, we weren't just watching immune memory develop after random infections - we were seeing it take shape in millions of people, almost at the same time. This meant researchers could track how the body learns and remembers in a way that had never really been possible before.

The mRNA vaccines - Pfizer and Moderna - were the first of their kind to be rolled out widely. They carry instructions for the spike protein, allowing the immune system to practice on a safe version of the virus's most important feature. The antibody response is dramatic: levels rise sharply within weeks. Then, as expected, they fall. At first, this looked worrying, but it quickly became clear that antibody decline was only part of the story. Memory B cells were still there, waiting, and even improving. Months after vaccination, these cells were producing antibodies that were better at recognizing the virus than the ones made at the beginning.

T cells also respond strongly. Both helper and killer T cells are activated by the vaccines, and unlike antibodies, their numbers don't fall off so quickly. A year later, T cell responses are still detectable. This long-lasting T cell memory is a major reason vaccinated people remain well protected from severe illness, even when they get infected.

Memory from natural infection and from vaccination isn't identical. Infection shows the body more than just the spike protein, which can give a wider range of responses. But it's unpredictable. People who had only mild symptoms often don't develop particularly strong memory, while those with severe illness usually do.

Vaccines are steadier. Almost everyone gets a solid antibody and T cell response. The downside is that vaccines target just the spike protein, which also happens to be the part of the virus that mutates most often. That means vaccine-induced antibodies are easier for new variants to dodge. Still, the T cell side

Investigating immunological memory in COVID-19 has shown us something remarkable: our bodies remember, adapt, and learn in addition to fighting. Long after the crisis has passed, that memory-quiet but persistent-serves as evidence of the immune system's extraordinary capacity to adjust and defend us.

of the memory tends to hold up, giving reliable protection against serious outcomes.

Perhaps the strongest memory of all comes from hybrid immunity - the combination of infection and vaccination. People with this mixed history usually show not just higher antibody levels, but also antibodies that recognize a wider variety of viral variants. Their T cells also look stronger and more flexible. It's as if the immune system, after being trained in two different ways, ends up more confident and adaptable.

The spread of new variants, especially Omicron, showed that antibody levels alone weren't enough. Booster shots helped fill the gap. They pushed antibody levels back up, but more importantly, they expanded the pool of memory B cells. These cells then produced antibodies that were better at recognizing the newer versions of the virus. Boosters also reinforced T cell memory, keeping the immune system alert.

What this meant in practice was clear during variant waves: people with boosters still got infected, but they were far less likely to end up in the hospital. In other words, boosters didn't erase the virus but they did tip the balance, turning potential severe cases into mild ones.

Even with their success, current vaccines aren't the end of the story. They do a good job at preventing severe disease, but they don't provide much mucosal immunity in the nose and throat, where the virus usually gets in. That's why researchers are testing nasal sprays and inhaled vaccines, which could stop the virus right at the entry point.(Krammer, 2021)

Other ideas are being explored too: variant-specific boosters, vaccines that protect against multiple coronaviruses at once, and even attempts at a universal coronavirus vaccine. These are ambitious goals, but the lessons from COVID-19 - especially how memory builds and lasts-make them feel more realistic than they might have seemed a few years ago.

Feature	Natural Infection	Vaccination	Hybrid Immunity
Antibody titters	Moderate, variable by severity	High, consistent	Highest and broadest
Memory B cells	Induced, quality varies	Strong and evolving	Most robust and diverse
$CD4^+$ T cell memory	Present, heterogeneous	Strong and durable	Enhanced coordination
$CD8^+$ T cell memory	Present, variable	Robust, platform-dependent	Strongest cytotoxic potential
Protection against severe disease	High	High	Highest
Variant coverage	Limited (wanes with variants)	Moderate	Broadest

Table 4 – Responses caused vaccine

("Elyahu Y, et al. CD8+ T cell memory signatures. Cell. 2022;185:250–269. - Google Search," n.d.)

8. Challenges and Open Questions in Understanding Immunological Memory to SARS-CoV-2

Even after years of deep research, there's still much about SARS-CoV-2 that puzzles immunologists. We know far more now than we did in 2020, but when it comes to how the immune system remembers this virus, there are still many blanks to fill in. Immune memory isn't a simple on–off switch; it changes depending on the virus, the host, and the circumstances of exposure. Add in new variants, human diversity, and environmental factors, and the picture gets even more complicated. Understanding all of this isn't just for curiosity's sake-it's the foundation for designing vaccines that last and preparing for whatever might come next.

A major unanswered question is how long protection actually lasts after someone recovers from infection or receives a vaccine. Antibody levels usually dip within months, but that doesn't necessarily mean immunity disappears. Memory B and T cells-sort of like the immune system's "archives"-can persist for years. In fact, a few long-term studies found that memory B cells targeting spike and nucleocapsid proteins don't fade quickly. Some even seem to improve their recognition accuracy over time. $CD4^+$ and $CD8^+$ T cells tend to stick around longer too, showing slower rates of decline.

But endurance isn't everything. What really matters is how good that memory is when it's called back into action. For instance, people who had severe infections tend to develop stronger and broader immune responses. However, too much inflammation can damage the germinal centres where B cells mature, which may reduce the quality of antibodies later on. The tricky part is that there's no clear line that defines what level of immunity is "enough." Interestingly, some people with low antibody levels don't get reinfected at all-likely because other immune layers, like memory T cells or non-neutralizing antibodies, quietly keep the virus under control.

Another big challenge is the virus itself-it won't sit still. The arrival of new variants like Alpha, Delta, and Omicron has reshaped what we thought we knew about immune memory. Small mutations, especially in the spike protein's receptor-binding domain (RBD) and N-terminal region, can weaken antibody attachment and give the virus a partial escape route. That's one reason why reinfections and breakthrough cases happen, even among vaccinated people, though symptoms are often milder.

What's worrying is that SARS-CoV-2 is evolving almost as fast as influenza now. Memory T cells still manage to recognize conserved viral regions, but even small changes can alter how antigens are presented to them. The long-term concern is whether future mutations could affect both antibody and T cell recognition at once. That's why scientists are pushing toward "pan-coronavirus" or "pan-sarbecovirus" vaccines-ones that target stable viral regions unlikely to mutate, aiming to create broader, long-lasting protection.

Immune memory doesn't form the same way in everyone. There's a lot of variation between people-shaped by age, genetics, lifestyle, past infections, and even the microbiome. Older adults, for example, experience immunosenescence, where the immune system slows down. They produce fewer naïve T cells and less diverse B cells, leading to weaker and shorter-lived memory responses. Younger people generally build stronger immunity but sometimes face an overzealous inflammatory reaction instead.

Underlying conditions like diabetes, obesity, and cardiovascular disease make things more complicated. They cause chronic low-grade inflammation that disrupts immune balance. On top of that, pre-existing T cells from exposure to other coronaviruses might offer some early protection but can also bias which viral fragments the immune system prioritizes. The result is a highly mixed picture, making it almost impossible to define one "standard" immune response for everyone. This diversity is why researchers are now talking more about personalized immunology-tailoring vaccine strategies to better fit individual immune landscapes.

It's strange how easy it is to forget that SARS-CoV-2 begins right where we breathe. The virus first takes hold in the nose, throat, and lungs, yet most vaccines are still injected into muscle. That's great for building systemic protection-plenty of circulating antibodies and T cells-but not ideal for the body's first line of defence.

Mucosal antibodies, mainly IgA, are the body's gatekeepers. They stop the virus before it spreads deeper, though they don't stick around long. And standard injections don't really refresh them. That's why nasal and oral vaccines have drawn so much attention; they might build stronger, more lasting immunity right at the front door.

There's still plenty we don't fully grasp. How long do mucosal antibodies linger? Do tissue-resident T cells in the airways coordinate with the circulating ones? Does hybrid exposure-natural infection plus vaccination-strengthen both systems at once? If scientists can untangle those questions, we might finally get vaccines that stop the virus before it gets started.

For years, everyone thought the innate immune system couldn't remember a thing. It was seen as the blunt, first responder-strong but forgetful. Now we know that's not the full story. Some innate cells, like macrophages and NK cells, can actually "remember" past signals and respond faster the next time. It's not precise memory like with antibodies or T cells, but it's a kind of readiness that lingers.

Older vaccines such as BCG or MMR seem to trigger this kind of training. There's even a bit of speculation that similar effects could shape how people respond to SARS-CoV-2. The tricky part is proving it. How long does that training last? How broad is it? And can it be enhanced safely without over activating the immune system?

If that mystery ever gets solved, trained immunity could become an unexpected tool-a way to prepare the immune system for future viruses before they even appear.

Here's something researchers often grumble about: we still don't have one clear marker that says, "Yes, this person is protected." Neutralizing antibodies are often used as the stand-in, but that doesn't tell the whole story. In severe disease, T cells probably matter more.

Testing doesn't make it easier. Different labs use different assays-ELISPOT, AIM, intracellular cytokine staining-and the results rarely match perfectly. It's a mess to compare across studies. What the field really needs are common standards and better multiplex tools that can measure multiple immune components at once.

Until that happens, it's hard to define what level of immunity truly prevents infection or severe illness-and for how long.

Now that COVID-19 isn't going away anytime soon, most people have mixed immune histories-some from infection, others from vaccines, and often both. This blend, called hybrid immunity, tends to offer broader protection than either one alone.

But nothing is simple. Could repeated exposure actually wear out the system? Nobody knows for sure. There's also the issue of *immune imprinting*-when the immune system clings to its memory of older variants and reacts less effectively to new ones. The challenge is balance: enough stimulation to keep memory fresh, but not so much that it confuses the immune system. Figuring out the right rhythm of exposure and boosting will probably take years-and might differ from person to person.

Then there's Long COVID-the slow echo of the infection that refuses to fade. Months after recovery, many people still deal with exhaustion, shortness of breath, or brain fog. Under the surface, their immune systems often look unsettled: inflammation that won't turn off, stray autoantibodies, and odd cytokine signals. Some researchers have even found traces of viral protein persisting in tissues, quietly keeping the immune system on alert.

What's not clear is whether this constant activity helps by reinforcing memory or harms by burning it out. Some suspect the latter-that it drains immune energy and leaves cells exhausted. Understanding that could reshape how we view chronic viral aftereffects, not just for COVID-19 but for other infections too.

The long-term goal is clear: vaccines that don't lose their punch as the virus changes. Scientists are already chasing "pan-coronavirus" designs that target stable viral pieces unlikely to mutate. The idea is to pair those with nasal or mucosal delivery, aiming for both internal and surface-level immunity. Thanks to advances in mRNA and nanoparticle technology, that dream doesn't feel far-fetched. These platforms allow fine-tuning of what the immune system sees and how it responds. The aim isn't just high antibody numbers-it's durable, well-placed memory B and T cells that can respond instantly at the site of infection.

Still, questions linger: what's the right antigen mix, how often should boosters come, and how do we adapt as the virus keeps evolving? Keeping global immune surveillance active-and sharing data freely-will be key to staying ahead.

Even with all we've learned, the story of SARS-CoV-2 and immune memory still feels half-written. Immunity isn't a fixed thing-it changes, adapts, and sometimes misfires. Working out how long protection lasts, how variants reshape it, and how personal biology steers it will refine not just COVID-19 strategies, but our understanding of viral memory itself.(Wheatley et al., 2021)

Every study adds one more piece to that puzzle, bringing us a step closer to vaccines and treatments that don't just react-but anticipate what comes next.

Challenge	Key Issues	Research Needs
Duration of protection	Antibody decline, uncertain B/T longevity	Long-term cohort studies
Variants and immune escape	Reduced antibody neutralization	Pan-variant vaccines
Heterogeneity of responses	Age, co-morbidities, genetics	Personalized vaccination
Mild vs severe infection	Stronger memory after severe infection	Stratified immunity studies
Mucosal immunity	Weak with intramuscular vaccines	Development of mucosal vaccines
Trained immunity	Unclear duration, role in protection	Mechanistic studies
Correlates of protection	No standardized marker	Integrated antibody, B/T cell measures

Table 5 – Challenges key issues and required research

("Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities | Signal Transduction and Targeted Therapy," n.d.; Saad-Roy et al., 2024; Sun et al., 2014)

9. Future Directions

Looking ahead, the lessons from COVID-19 don't just apply to this virus. They've reshaped how we think about immune memory in general and how we prepare for the next outbreak. Some paths forward seem clear, while others are still only ideas on the drawing board. Either way, it's hard to ignore that the last few years taught us more about memory than anyone expected.

Coronaviruses have jumped into humans more than once - SARS in 2003, MERS in 2012, and then SARS-CoV-2. It would be naïve to think it won't happen again. That's why the push for a pan-coronavirus vaccine is so strong. The idea is simple: find the viral parts that don't change much and build immunity against those. Simple to say, not simple to do. But if it works, it could blunt the impact of whatever coronavirus shows up next.

Most infections start in the nose and throat, yet today's vaccines are injected into the arm. That mismatch explains why people still get infected even after being vaccinated. A mucosal vaccine, taken through a spray or inhaled, could set up defences right at the entry point. IgA antibodies in the nose, tissue-resident T cells in the airways-this is the sort of protection that might actually block infection before it takes off. Early trials are underway, and results are mixed so far, but the logic behind the approach is hard to argue with.

Hybrid immunity - mixing infection and vaccination - clearly provides the strongest protection. Of course, it's not practical or ethical to let people get infected as part of policy. But researchers are wondering: could vaccine regimens be designed to mimic that effect? Maybe using different types of vaccines in sequence, or broader multivalent ones, could give a similar benefit without the risks of natural infection. It's still speculative, but it's a natural question to ask.Immune responses aren't the same for everyone. Older adults, people with weak

immune systems, and even differences in genetics all change how memory develops. It seems unlikely that one schedule or one dose size works equally well for everyone. In the future, vaccination might need to look more personalized - stronger doses for some, different formulations for others. We already adjust vaccines for age in flu shots, so it wouldn't be an entirely new idea.

Variants showed us that the virus is always moving. Staying ahead of it means watching its genome closely and linking that to how immunity holds up in real people. In practice, that means combining surveillance with immunological data, and ideally using that information to tweak vaccines before a new variant spreads widely. The infrastructure for global monitoring exists, but making it faster and better connected is the challenge.

10. Conclusion

The story of immune memory in COVID-19 is still being written. What we know so far is encouraging: vaccines and natural infection both create layers of memory that don't disappear overnight. Antibodies fall, yes, but memory B cells and T cells remain, and together they form a safety net that keeps most infections from turning deadly. That balance between short-term decline and long-term resilience is one of the most striking lessons of the pandemic.

At the same time, there are limits. Variants continue to slip past antibody defences, and reinfections remind us that immunity isn't perfect. Breakthrough cases have become part of the landscape, though they rarely lead to the kind of severe disease seen in the early months of the pandemic. In that sense, immune memory doesn't stop the virus entirely - it reshapes the outcome, turning what might have been life-threatening into something more manageable.

The experience also highlighted how much we still don't know. How long will memory last? Can vaccines be designed to give the kind of lifelong protection we see with measles, or will COVID-19 settle into a pattern more like flu, with regular updates and boosters? These are questions without final answers.

What is clear is that the science of immune memory has moved forward faster in a few years than it had in decades before. COVID-19 forced researchers to study immune responses at a scale and speed never attempted before. The insights gained - on B cells, T cells, hybrid immunity, and mucosal defences - will shape not only how we handle this virus, but how we prepare for the next one.

In the end, memory is about more than cells and molecules. It's also about what societies choose to remember. If the scientific lessons of this pandemic are carried forward, they could make the difference between being caught off guard again or being ready when the next challenge arrives.(Sterlin et al., 2021)

Trained immunity is a newer concept, but it might be useful when time is short. In the early stages of a pandemic, when no specific vaccine is ready, something that boosts innate immunity - even if nonspecific - could make a difference. BCG has been studied for this reason, and while the results aren't conclusive, the idea hasn't been abandoned. It won't replace adaptive memory, but as a stopgap, it could buy time.(Pradenas et al., 2023)

The biggest takeaway may be the simplest: we need to be better prepared. COVID-19 made clear that rapid vaccine platforms, strong international coordination, and

deeper knowledge of long-term immunity aren't luxuries - they're necessities. Memory isn't just a scientific concept here; it's also what societies need to carry forward, so we don't repeat the same mistakes when the next virus arrives.

References

1. Adamo, S., Michler, J., Zurbuchen, Y., Cervia, C., Taeschler, P., Raeber, M.E., Baghai Sain,S., Nilsson, J., Moor, A.E., Boyman, O., 2022. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection. Nature 602, 148–155.
2. Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez, S.I., Haupt, S., Frazier, A., Nakao, C., Rayaprolu, V., Rawlings, S.A., Peters, B., Krammer, F., Simon, V., Saphire, E.O., Smith, D.M., Weiskopf, D., Sette, A., Crotty, S., 2021. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371,
3. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities | Signal Transduction and Targeted Therapy

4. Dupont, L., Snell, L.B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Hallett, S.R., Charalampous, T., Alcolea-Medina, A., Huettner, I., Maguire, T.J.A., Acors, S., Almeida, N., Cox, D., Dickenson, R.E., Galao, R.P., Jimenez-Guardeño, J.M., Kouphou, N., Lista, M.J., Pickering, S., Ortega-Prieto, A.M., Wilson, H., Winstone, H., Fairhead, C., Su, J., Nebbia, G., Batra, R., Neil, S., Shankar-Hari, M., Edgeworth, J.D., Malim, M.H., Doores, K.J., 2021. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections. medRxiv 2021.06.07.21258351.
5. Elyahu Y, et al. CD8+ T cell memory signatures. Cell. 2022;185:250–269.
6. Gaebler, C., Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T.Y., Cipolla, M., Viant, C., Barnes, C.O., Bram, Y., Breton, G., Hägglöf, T., Mendoza, P., Hurley, A., Turroja, M., Gordon, K., Millard, K.G., Ramos, V., Schmidt, F., Weisblum, Y., Jha, D., Tankelevich, M., Martinez-Delgado, G., Yee, J., Patel, R., Dizon, J., Unson-O'Brien, C., Shimeliovich, I., Robbiani, D.F., Zhao, Z., Gazumyan, A., Schwartz, R.E., Hatziioannou, T., Bjorkman, P.J., Mehandru, S., Bieniasz, P.D., Caskey, M., Nussenzweig, M.C., 2021. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644.
7. Harms Pritchard, G., Pepper, M., 2018. Memory B cell heterogeneity: Remembrance of things past. J. Leukoc. Biol. 103, 269–274.
8. Krammer, F., 2021. Correlates of protection from SARS-CoV-2 infection. The Lancet 397, 1421–1423.
9. Minervina, A.A., Komech, E.A., Titov, A., Bensouda Koraichi, M., Rosati, E., Mamedov, I.Z., Franke, A., Efimov, G.A., Chudakov, D.M., Mora, T., Walczak, A.M., Lebedev, Y.B., Pogorelyy, M.V., 2021. Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection. eLife 10, e63502.
10. Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M.A., Tano-Menka, R., Ofoman, O., Gayton, A., Senjobe, F., Zhao, Z., Denis, K.J.S., Lam, E.C., Carrington, M., Garcia-Beltran, W.F., Balazs, A.B., Walker, B.D., Iafrate, A.J., Gaiha, G.D., 2022. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell 185, 1041-1051.e6.
11. Pradenas, E., Marfil, S., Urrea, V., Trigueros, M., Pidkova, T., Pons-Grífols, A., Ortiz, R., Rovirosa, C., Tarrés-Freixas, F., Aguilar-Gurrieri, C., Toledo, R., Chamorro, A., Noguera-Julian, M., Mateu, L., Blanco, I., Grau, E., Massanella, M., Carrillo, J., Clotet, B., Trinité, B., Blanco, J., 2023. Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. iScience 26.
12. Saad-Roy, C.M., Morris, S.E., Boots, M., Baker, R.E., Lewis, B.L., Farrar, J., Marathe, M.V., Graham, A.L., Levin, S.A., Wagner, C.E., Metcalf, C.J.E., Grenfell, B.T., 2024. Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy. PLoS Comput. Biol. 20,
13. Sette, A., Crotty, S., 2021. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861–880.
14. Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J., Devilliers, H., Ghillani, P., Gunn, C., Hockett, R., Mudumba, S., Guihot, A., Luyt, C.-E., Mayaux, J., Beurton, A., Fourati, S., Bruel, T., Schwartz, O., Lacorte, J.-M., Yssel, H., Parizot, C., Dorgham, K., Charneau, P., Amoura, Z., Gorochov, G., 2021. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223.
15. Sun, J.C., Ugolini, S., Vivier, E., 2014. Immunological memory within the innate immune system. EMBO J. 33, 1295–1303.
16. Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin, B., Phillips, E., Mallal, S., Sidney, J., Filaci, G., Weiskopf, D., da Silva Antunes, R., Crotty, S., Grifoni, A., Sette, A., 2022. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847-859.e11.
17. Tomic, A., Skelly, D.T., Ogbe, A., O'Connor, D., Pace, M., Adland, E., Alexander, F., Ali, M., Allott, K., Azim Ansari, M., Belij-

Rammerstorfer, S., Bibi, S., Blackwell, L., Brown, A., Brown, H., Cavell, B., Clutterbuck, E.A., de Silva, T., Eyre, D., Lumley, S., Flaxman, A., Grist, J., Hackstein, C.-P., Halkerston, R., Harding, A.C., Hill, J., James, T., Jay, C., Johnson, S.A., Kronsteiner, B., Lie, Y., Linder, A., Longet, S., Marinou, S., Matthews, P.C., Mellors, J., Petropoulos, C., Rongkard, P., Sedik, C., Silva-Reyes, L., Smith, H., Stockdale, L., Taylor, S., Thomas, S., Tipoe, T., Turtle, L., Vieira, V.A., Wrin, T., Pollard, A.J., Lambe, T., Conlon, C.P., Jeffery, K., Travis, S., Goulder, P., Frater, J., Mentzer, A.J., Stafford, L., Carroll, M.W., James, W.S., Klenerman, P., Barnes, E., Dold, C., Dunachie, S.J., 2022. Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nat. Commun. 13, 1251.

18. Turner, J.S., Kim, W., Kalaidina, E., Goss, C.W., Rauseo, A.M., Schmitz, A.J., Hansen, L., Haile, A., Klebert, M.K., Pusic, I., O'Halloran, J.A., Presti, R.M., Ellebedy, A.H., 2021. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421–425. https://doi.org/10.1038/s41586-021-03647-4
19. Wheatley, A.K., Juno, J.A., Wang, J.J., Selva, K.J., Reynaldi, A., Tan, H.-X., Lee, W.S., Wragg, K.M., Kelly, H.G., Esterbauer, R., Davis, S.K., Kent, H.E., Mordant, F.L., Schlub, T.E., Gordon, D.L., Khoury, D.S., Subbarao, K., Cromer, D., Gordon, T.P., Chung, A.W., Davenport, M.P., Kent, S.J., 2021. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162.

*****